O'Mahony Seamus
Cork University Hospital, Wilton, Cork, Ireland.
IDrugs. 2005 Jun;8(6):502-7.
Otsuka is developing a once-daily oral formulation of the phosphodiesterase-4 inhibitor tetomilast for the potential treatment of ulcerative colitis (phase III) and chronic obstructive pulmonary disease (phase II).
大冢制药正在研发磷酸二酯酶-4抑制剂替托司特的每日一次口服制剂,用于潜在治疗溃疡性结肠炎(III期)和慢性阻塞性肺疾病(II期)。